Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
113 hedge funds and large institutions have $1.08B invested in Verona Pharma in 2024 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 44 increasing their positions, 28 reducing their positions, and 19 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 28
0.31% less ownership
Funds ownership: 10.64% → 10.34% (-0.31%)
3% less funds holding
Funds holding: 117 → 113 (-4)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
19% less call options, than puts
Call options by funds: $1.26M | Put options by funds: $1.55M
20% less capital invested
Capital invested by funds: $1.36B → $1.08B (-$270M)
21% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CP
Caligan Partners
New York
|
+$19.3M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$14M |
| 3 |
ABG
Ally Bridge Group
New York
|
+$12.7M |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$9.88M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$5.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$54.8M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$15.5M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$11.1M |
| 4 |
Morgan Stanley
New York
|
-$10.9M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.25M |
VRNA Hedge Fund Activity: Q1 2024 in Review
113 of the 6,934 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q1 2024, worth a combined $1.08B — down 20% from $1.36B a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of VRNA and 15 opened new positions — a net loss of 4 holders — while 28 trimmed existing stakes and 44 added.
The largest buyer was Caligan Partners, adding an estimated $19.3M. The largest seller was Fidelity Investments, cutting an estimated $54.8M.
- 113 institutional investors held Verona Pharma (VRNA) as of Q1 2024, down from 117 in Q4 2023.
- Funds reported $1.08B of Verona Pharma stock for Q1 2024, down 20% quarter-over-quarter.
- 15 funds opened new Verona Pharma positions in Q1 2024 and 19 closed out, a net change of -4 holders.
- The largest Verona Pharma buyer in Q1 2024 was Caligan Partners, an estimated $19.3M added.
- The largest Verona Pharma seller in Q1 2024 was Fidelity Investments, an estimated $54.8M sold.
Based on aggregated 13F filings for Q1 2024.